Given the long period of disease progression, we employed a long-term administration scheme in a pristane-induced lupus model, which revealed that L72-FSY and PEG-L72FSY diminished the activity of Teffs to a greater extent than treatment with WT-IL-2, as demonstrated by the considerably decreased frequencies of CD8+ T and CD69+ Tconv cells. This evidence concerns the gene IL2 and systemic lupus erythematosus.